The Market For Prescription Antiviral Drugs

Report Highlights

• The market has grown by more than $840 million since 2000 and more than $1.4 billion since 1999.
• By 2006, it is anticipated that revenues will likely reach $13.92 billion, growing at an average annual growth rate of 8.4%.

INTRODUCTION 

STUDY GOLAS AND OBJECTIVES

The Global Market for Prescription Antiviral Drugs is designed to provide the reader with a comprehensive analysis of viruses and the drugs to treat diseases caused by viruses. Each segment provides an overview of significant treatments and market size and growth for global markets. Markets are divided according to drug class. The report is directed to decision-makers in the various areas of prescription antivirals to present insight into those areas for current and future development.

REASONS FOR DOING THE STUDY

This BCC study is presented to heighten the awareness of antiviral therapy and the diseases that are involved in that therapy. The study analyzes current antiviral therapies as well as innovative products in development. Because viral infections are central to many catastrophic diseases, it is important for anyone in the medical field to understand this area of medicine and its implications on the entire healthcare arena.

CONTRIBUTION OF THE STUDY AND FOR WHOM

This report provides a thorough background of antiviral therapy and its profound impact on the treatment of various diseases. The study is an invaluable tool for business planners, acquisitions specialists, licensing strategists, product managers, market research analysts, investor consultants, and anyone interested in the antiviral market and its immense potential.

SCOPE AND FORMAT

The report is designed to be a comprehensive business tool offering an in-depth look at the antiviral market accompanied by analyses and forecasts by drug class. The geographic scope of the report is worldwide. International efforts in the antiviral market are discussed, as well as information on participants and financial impacts. Profiles of leading companies provide strategic analyses of various companies’ emerging products as well as products currently on the market. The market is presented by detailing its relationship to the healthcare industry, its participants, and its trends for the future.

The global market for antiviral drugs is divided into categories by drug classification as follows:

• Nucleoside analog and nucleoside reverse transcriptase inhibitors
• Non-nucleoside analog reverse transcriptase inhibitors
• Protease inhibitors
• Other antiviral drugs

Each segment is discussed in detail, describing the class of drug, identifying products participating in the market, measuring current market size and forecasting potential market size based on current and potential market drivers and trends, and current competitor market shares.

METHODOLOGY

The information and analysis presented in this BCC report are based on extensive firsthand interviews with primary executives, product managers, and clinical specialists in the prescription antiviral arena. Background information was obtained from various government, business, medical journal and trade magazines and interviews with doctors and nurses. Key information from published literature was used to conduct interviews with approximately 50 industry participants to validate and obtain expert opinions on current and future trends in the antiviral market. Interviews were also used to confirm and/or adjust market size and market share estimates, as well as formulating market projections.

All market data pertain to the worldwide market at the manufacturers’ level. Data are expressed in current U.S. dollars. The base year is 2001. Historical data are provided for 1999 and 2000 and forecast data are provided for 2006. Historical, base year and forecast data are provided for each market segment. Market shares are provided for each market segment for the 2001 base year.